Frontage Holdings Corp. (1521) Price & Analysis

Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.